Core Insights - GoodRx Holdings, Inc. reported revenue of $202.97 million for Q1 2025, a year-over-year increase of 2.6% and an EPS of $0.09, compared to $0.08 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $202.59 million, resulting in a surprise of +0.19% [1] - The company did not deliver an EPS surprise, as the consensus EPS estimate was also $0.09 [1] Performance Metrics - GoodRx's shares returned +4.2% over the past month, while the Zacks S&P 500 composite increased by +10.6% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential outperformance against the broader market in the near term [3] Key Company Metrics - Monthly Active Consumers: 6 million, below the estimated 7 million [4] - Subscription plans: 680 thousand, slightly below the estimated 685 thousand [4] - Revenue from Prescription transactions: $148.92 million, exceeding the estimate of $146.53 million, representing a +2.4% year-over-year change [4] - Revenue from Other sources: $4.38 million, below the estimate of $5.47 million, reflecting a year-over-year decline of -18.5% [4] - Revenue from Pharma manufacturer solutions: $28.65 million, slightly below the estimate of $29.90 million, but showing a +16.9% year-over-year increase [4] - Revenue from Subscription: $21.02 million, above the estimate of $20.79 million, but down -7% year-over-year [4]

Core Viewpoint - GoodRx Holdings, Inc. reported quarterly earnings of $0.09 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.08 per share a year ago [1] - The company posted revenues of $202.97 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 0.19% and up from $197.88 million year-over-year [2] Financial Performance - GoodRx's earnings have not surpassed consensus EPS estimates over the last four quarters [1] - The company has topped consensus revenue estimates only once in the past four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $205.65 million, and for the current fiscal year, it is $0.40 on revenues of $824.14 million [7] Market Performance - GoodRx shares have declined approximately 8.4% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Outlook - The Medical Services industry, to which GoodRx belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact GoodRx's stock performance [5]

Revenue Performance - Revenue increased by 3% to $203.0 million from $197.9 million[102] - Total revenue for Q1 2025 was $202.97 million, a 1.1% increase from $197.88 million in Q1 2024[120] - Prescription transactions revenue increased by $3.5 million, or 2%, year-over-year, totaling $148.92 million in Q1 2025[123] - Subscription revenue decreased by $1.6 million, or 7%, year-over-year, totaling $21.02 million in Q1 2025[124] - Pharma manufacturer solutions revenue increased by $4.1 million, or 17%, year-over-year, totaling $28.65 million in Q1 2025[125] Profitability - Net income was $11.1 million with a net income margin of 5.4%, compared to a net loss of $1.0 million and a net loss margin of 0.5% in the previous year[102] - Operating income for Q1 2025 was $23.38 million, compared to $7.38 million in Q1 2024[122] - Net income for Q1 2025 was $11.05 million, a significant improvement from a net loss of $1.01 million in Q1 2024[122] - Adjusted EBITDA rose to $69.8 million, with an Adjusted EBITDA Margin of 34.4%, up from $62.8 million and 31.7% respectively[102] Consumer Metrics - Monthly Active Consumers decreased to 6.4 million in Q1 2025 from 6.7 million in Q1 2024[106] - Subscription plans totaled 680,000 as of March 31, 2025, down from 778,000 a year earlier[108] - The company expects a year-over-year decline in Monthly Active Consumers in the near term due to changes in retail pharmacy reimbursement models[105] Cash Flow and Financial Position - Cash and cash equivalents as of March 31, 2025, were $301.0 million, with $91.7 million available under a revolving credit facility[135] - Net cash provided by operating activities decreased by $33.2 million year-over-year, totaling $9.41 million in Q1 2025[142] - Net cash used in investing activities increased by $31.3 million year-over-year, primarily due to a $30.0 million increase in cash paid for business acquisition[143] - General and administrative expenses decreased by $11.5 million, or 28%, year-over-year, totaling $29.63 million in Q1 2025[130] Strategic Outlook - Revenue from Rite Aid is forecasted to be less than 5% of total revenue in 2025 due to store closures and bankruptcy proceedings[100] - The company aims to build a leading consumer-focused digital healthcare platform in the U.S. to address rising copays on prescription medications[99] - The company anticipates that prescription volume will migrate to other in-network pharmacies despite the adverse impact from retail pharmacy changes[100] - Adjusted Revenue for Q1 2025 was equal to reported revenue, excluding client contract termination costs[110]

Revenue Performance - First Quarter 2025 revenue increased by 3% to $203.0 million compared to $197.9 million in the same period last year[3] - Total revenue for Q1 2025 was $202.97 million, up 2.2% from $197.88 million in Q1 2024[30] - Revenue for Q1 2025 was $202,970,000, a 1.1% increase from $197,880,000 in Q1 2024[45] - For the full year 2025, the company anticipates revenue between $810 million and $840 million, representing a 2% to 6% growth compared to 2024[12] Segment Performance - Prescription transactions revenue rose by 2% to $148.9 million, driven by improved unit economics, despite a 4% decrease in Monthly Active Consumers[4] - Subscription revenue decreased by 7% to $21.0 million, primarily due to the discontinuation of the Kroger Savings Club partnership[5] - Pharma manufacturer solutions revenue increased by 17% to $28.6 million, reflecting organic growth and expanded market penetration[6] Profitability Metrics - Net income for the first quarter was $11.1 million, with a net income margin of 5.4%, compared to a net loss of $1.0 million in the prior year[6] - Net income for Q1 2025 was $11.05 million, a significant improvement from a net loss of $1.01 million in Q1 2024[30] - Adjusted Net Income for Q1 2025 was $34,363,000, compared to $32,586,000 in Q1 2024, showing a year-over-year increase of 5.4%[45] - Basic earnings per share for Q1 2025 was $0.03, compared to $(0.00) in Q1 2024, indicating a positive shift in profitability[45] Operational Efficiency - Adjusted EBITDA was $69.8 million, with an Adjusted EBITDA margin of 34.4%, up from 31.7% in the previous year[7] - Adjusted EBITDA for Q1 2025 reached $69,805,000, up from $62,787,000 in Q1 2024, indicating a growth of approximately 16%[42] - Adjusted EBITDA margin for Q1 2025 was 34.4%, up from 31.7% in Q1 2024, reflecting improved operational efficiency[42] - Operating income for Q1 2025 was $23.38 million, compared to $7.38 million in Q1 2024, an increase of 216.5%[30] - Operating income for Q1 2025 was $23,380,000, significantly higher than $7,381,000 in Q1 2024, indicating strong operational performance[49] Cash Flow and Assets - Cash flow from operating activities was $9.4 million, down from $42.6 million in the same quarter last year[8] - Cash and cash equivalents decreased to $300.98 million as of March 31, 2025, down from $448.35 million at the end of 2024, a reduction of 32.9%[27] - Total assets decreased to $1.30 billion in March 2025 from $1.39 billion in December 2024, a decline of 6.7%[27] - Total liabilities decreased to $640.92 million in March 2025 from $663.41 million in December 2024, a reduction of 3.4%[28] Consumer Metrics - The company exited the first quarter with over 7 million prescription-related consumers using GoodRx services[24] - Monthly Active Consumers decreased to 6.4 million in March 2025 from 6.6 million in December 2024, representing a decline of 3%[25] - Subscription plans decreased to 680,000 in March 2025 from 778,000 in March 2024, a decline of 12.6%[25] Cost Management - Total stock-based compensation expense for Q1 2025 was $19,174,000, down from $25,096,000 in Q1 2024, suggesting cost management efforts[45] - General and administrative expenses decreased to $29,630,000 in Q1 2025 from $41,108,000 in Q1 2024, representing a reduction of approximately 28%[47] Acquisition Costs - The company incurred $30 million in acquisition costs during Q1 2025[32] Future Guidance - Adjusted EBITDA guidance for 2025 is now between $273 million and $287 million, indicating a 5% to 10% growth compared to the previous year[12] - Adjusted EBITDA for Q1 2025 is expected to align with revenue, indicating stable operational performance moving forward[34]

Group 1 - Value stocks have lost favor as investors focus on high-growth stocks, particularly those linked to the AI industry [1] - There is a notable decline in valuation multiples due to concerns about a potential U.S. recession [1] - Gary Alexander has extensive experience in technology sectors, both on Wall Street and in Silicon Valley, influencing current industry themes [1]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-K __________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____. Commission File Number: 001-3 ...

GoodRx Holdings Inc. GDRX reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and consensus of $199.75 million.Fiscal year sales of $792.3 million came in below the guidance of around $794 million.The company reported adjusted EPS of 9 cents, up from 8 cents a year ago, missing the consensus of 10 cents.Q4 prescription transactions revenue increased 0.8% to $144.9 million. 2024 prescription transactions revenue increased ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director, IR Wendy Barnes - CEO Chris McGinnis - CFO Conference Call Participants Lisa Gill - J.P. Morgan John Ransom - RJF Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jenny Cao - Truist Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Steven Valiquette - Mizuho Securities Jay Jin - Morgan Stanley George Hill - Deutsche Bank Allen Lutz - ...

For the quarter ended December 2024, GoodRx Holdings, Inc. (GDRX) reported revenue of $198.58 million, up 1% over the same period last year. EPS came in at $0.09, compared to $0.08 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $199.81 million, representing a surprise of -0.62%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.09.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Financial Data and Key Metrics Changes - For Q4 2024, revenue was $198.6 million, and adjusted EBITDA was $67.1 million, leading to a full year revenue of $792.3 million, a 6% increase year-over-year on a GAAP basis [29] - Full year adjusted EBITDA was $260.2 million, representing a 20% growth over 2023 [30] - Net income for 2024 was $16.4 million compared to a net loss of $8.9 million in 2023, while adjusted net income increased to $131.6 million from $114.6 million in 2023 [30][31] - Adjusted EBITDA margin improved to 32.8%, marking another year of margin expansion [30][32] Business Line Data and Key Metrics Changes - Prescription transactions revenue grew 5% year-over-year to $577.5 million, primarily due to a 7% increase in monthly active consumers [29][30] - Subscription revenue declined 8% to $86.5 million, largely due to the sunset of a retailer-specific prescription savings program [30] - Pharma manufacturer solutions revenue increased by 26% year-over-year to $107.2 million [30] Market Data and Key Metrics Changes - Nearly 30 million consumers used GoodRx in 2024, saving approximately $17 billion on medications, with a 3% year-over-year growth in the prescription discount segment [14][29] - The company's share of the prescription discount segment grew by 3% year-over-year in Q4 2024 [14] Company Strategy and Development Direction - The company aims to enhance the prescription experience for consumers and healthcare professionals, focusing on reducing friction and improving access to medications [10][12] - GoodRx is expanding its Integrated Savings Program (ISP) to include non-covered brands, addressing gaps in coverage and enhancing value for consumers and healthcare professionals [17][25] - The company is also increasing its partnerships with pharma manufacturers, growing from 150 to over 200 brands in 2024, and focusing on integrated access solutions and e-commerce capabilities [18][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the opportunities to make healthcare more affordable and accessible, particularly in light of potential regulatory changes favoring transparency and lower prices [13][28] - The company anticipates revenue growth in 2025 to be in the range of $810 million to $840 million, representing approximately 4% growth at the midpoint [33] - Management acknowledged potential headwinds from pharmacy store closures but remains confident in the overall growth trajectory of prescription transaction revenue [102] Other Important Information - The company has a strong balance sheet with $448.3 million in cash on hand and $500 million in outstanding debt, providing significant liquidity [32] - GoodRx is committed to returning excess cash to shareholders through share repurchases, with $290 million authorized for spend [75] Q&A Session Summary Question: How many new initiatives are included in the guidance? - Management indicated that the guidance accounts for some expansion in manufacturer programs and marketplace growth, particularly in brand expansion [39][40] Question: Can you comment on the pharma manufacturing solutions growth? - Management remains confident in achieving 20% growth in pharma manufacturer solutions, citing a significant increase in partnerships and validated results [48][49] Question: What is the current status of ISP rollouts with PBM partners? - Management noted ongoing discussions with PBM partners and emphasized the importance of wrapping non-covered brands to enhance value [56][58] Question: What are the headwinds reflected in the guidance? - Management acknowledged potential headwinds from pharmacy store closures but expects overall growth in prescription transaction revenue [102]